IPP Bureau
Emcure Pharmaceuticals launches solution for menopause wellness ‘Arth’ in India
By IPP Bureau - September 05, 2024
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
By IPP Bureau - September 05, 2024
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
Alkem signs license agreement with Takeda to commercialise Vonoprazan in India
By IPP Bureau - September 04, 2024
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Enzene appoints new site lead of biologics manufacturing
By IPP Bureau - September 04, 2024
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
AstraZeneca advances ambition to improve standards of care in multiple cancer types
By IPP Bureau - September 04, 2024
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression
By IPP Bureau - September 04, 2024
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
By IPP Bureau - September 04, 2024
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
STEER World appoints Dhiraj Tiwari as CFO
By IPP Bureau - September 04, 2024
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
Siegfried opens quality control lab in Minden
By IPP Bureau - September 04, 2024
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis
By IPP Bureau - September 04, 2024
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
Lupin launches Mirabegron ER tablets in US
By IPP Bureau - September 04, 2024
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
Jubilant Ingrevia appoints Birajeev Suresh Singh as SVP – Supply Chain
By IPP Bureau - September 03, 2024
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
Lupin launches Doxorubicin Hydrochloride Liposome Injection in US
By IPP Bureau - September 03, 2024
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Roche’s PiaSky approved in the EU for treatment of people with PNH
By IPP Bureau - September 03, 2024
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Tolebrutinib meets primary endpoint in HERCULES phase 3 study
By IPP Bureau - September 03, 2024
Phase 3 study results will form the basis for future discussions with global regulatory authorities
